GMPPB

Across TCGA pan-cancer cohorts, GMPPB mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GMPPB data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GMPPB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GMPPB expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, GBM, and LSCC are the cancer types where GMPPB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.716	0.341	<.001	30	view →
GBM	DFS	Median	All	0.282	0.454	.002	16	view →
LSCC	DFS	Tertile	II,III,IV	0.506	0.854	.011	10	view →
LUAD	DFS	Quartile	All	0.933	0.833	.011	10	view →
UCEC	DFS	Tertile	All	0.974	0.844	.015	8	view →
HNSC	DFS	Median	IV	0.881	0.667	.027	6	view →
CCRCC	OS	Median	All	0.906	1.000	.016	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GMPPB–PDAC (OS)

Open the PDAC breakdown →